Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Exclusion Criteria

• •* Acute lymphoblastic leukemia
• •* Chronic myelogenous leukemia (CML)
• •* Documented hematologic resistance to imatinib mesylate OR no cytogenetic response after 12 months of prior treatment with imatinib mesylate
• •* Philadelphia chromosome-negative CML allowed provided disease is resistant to standard therapy (e.g., hydroxyurea) OR disease progressed (blasts \> 5% and platelet count \< 100,000/mm\^3) during standard therapy
• •* Myelodysplastic syndromes
• •* International Prognostic Scoring System risk category ≥ intermediate-1
• •* Myeloproliferative disease
• •* Chronic lymphocytic leukemia
• •* Failed or progressed during ≥ 1 prior fludarabine-based therapy AND alemtuzmab
• •* Acute promyelocytic leukemia
• •* Progressed after prior treatment with standard chemotherapy, tretinoin, and arsenic trioxide
• •* Chronic myelomonocytic leukemia
• •* Resistant to standard therapy (e.g., hydroxyurea) OR disease progressed (blasts \> 5% and platelet count \< 100,000/mm\^3) during standard therapy
• •Relapsed or refractory disease
• •No known brain or meningeal disease
• •PATIENT CHARACTERISTICS:
• •Age
• •Over 18
• •Performance status
• •ECOG 0-1
• •Life expectancy
• •More than 8 weeks
• •Hepatic
• •Bilirubin \< 2 mg/dL
• •AST and ALT ≤ 2.5 times upper limit of normal
• •Renal
• •Creatinine \< 2 mg/dL
• •Cardiovascular
• •QTc \< 500 msec
• •LVEF \> 40% by MUGA
• •No New York Heart Association class III or IV congestive heart failure
• •No myocardial infarction within the past year
• •No uncontrolled dysrhythmias
• •No uncontrolled angina
• •No left ventricular hypertrophy by EKG
• •No history of serious ventricular arrhythmia (e.g., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
• •No other significant cardiac disease
• •Immunologic
• •No history of allergic reaction attributed to compounds of similar chemical or biologic composition to study drugs
• •No ongoing or active infection
• •No HIV positivity
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No psychiatric illness or social situation that would preclude study compliance
• •No other uncontrolled illness
• •PRIOR CONCURRENT THERAPY:
• •Chemotherapy
• •Recovered from prior chemotherapy
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) unless there is evidence of rapidly progressive disease
• •Radiotherapy
• •At least 4 weeks since prior radiotherapy and recovered
• •Other
• •No concurrent agents that cause QTc prolongation
• •No other concurrent investigational or commercial agents or therapies for the malignancy
• •No concurrent hydrochlorothiazide
• •* Concurrent potassium-conserving combinations (e.g., Maxide® or Dyazide®) or other antihypertensive agents allowed